Guided Thera Stock Price, News & Analysis

Guided Therapeutics (OTCQB: GTHP) has completed patient testing for its LuViva Advanced Cervical Scan in a clinical trial seeking NMPA approval in China. The trial, conducted at four sites, involved 150 patients and is expected to conclude in Q2 2023 for subsequent submission. The company received a milestone payment of $177,740 from its partner SMI, which will help supply LuViva devices. Preliminary results indicate good safety and accuracy, supporting the trial's continuation and the upcoming submission.

Guided Therapeutics (GTHP) has commenced patient enrollment and testing for its LuViva Advanced Cervical Scan at the Department of Obstetrics & Gynecology Hospital of Fudan University in Shanghai. This pivotal clinical trial is integral to the company's international commercialization strategy. Upon submission of data to the Chinese NMPA, GTHP is set to receive $620,000 from its partner, Shandong Yaohua Medical Instrument Corporation, with an additional $1.88 million due post-marketing approval. Cervical cancer remains a critical health issue in China, with the LuViva device providing timely screening benefits.

Guided Therapeutics, Inc. (GTHP) announced that its Chinese partner, Shandong Yaohua Medical Instrument Corporation, received ethics board approval for clinical trials using LuViva devices at three hospitals. The study, involving about 400 patients, is set to begin next month. SMI ordered additional LuViva devices, with $100,000 paid towards a total purchase order of $530,000. Another order for $2.5 million is contingent on the filing of clinical study results and subsequent FDA approval in China, with minimum orders of $72 million anticipated post-approval.

Guided Therapeutics (OTCQB: GTHP) announced successful regulatory compliance for its LuViva® Advanced Cervical Scan at Fudan University in Shanghai, paving the way for clinical trials this quarter. The company secured $133,000 from partner Shandong Yaohua Medical Instrument Corporation, aimed at supporting clinical studies in China. Anticipating $3 million in payments by year-end, contingent on Chinese FDA approval, GTHP could receive $510,000 during the trials. Cervical cancer remains a critical health issue in China, indicating a substantial market opportunity for LuViva's point-of-care technology.

Guided Therapeutics, Inc. (OTCQB: GTHP) announced impressive results from an independent study of its LuViva Advanced Cervical Scan. The study with 166 women in Hungary showed LuViva detected 20% more cervical precancer and cancer than the HPV test, boasting a sensitivity of 94%. LuViva also provides immediate results without the need for extensive lab infrastructure. The device has received CE Mark and is set for launch in Central and Eastern Europe this year. The Hungarian medical community sees LuViva as a significant improvement in cervical screening quality.

Guided Therapeutics (OTCQB: GTHP) has announced that its LuViva™ Advanced Cervical Scan has passed safety and electromagnetic compliance tests required for clinical trials in China. The clinical trials, set to begin this quarter, are critical for obtaining Chinese FDA approval and initiating sales, which SMI anticipates in the second half of 2022. With cervical cancer being a significant health issue in China, affecting approximately 560 million women, this milestone represents a crucial step forward for the company's expansion in the Chinese market.

Guided Therapeutics (OTCQB: GTHP) announced the raising of US $1.13 million through a 3-year convertible debenture, aimed at repaying a dilutive convertible note due at 2021's end. The new debenture has a fixed conversion price of $0.50, reducing shareholder dilution compared to the retired note. Additionally, it will convert automatically into securities during a future financing related to a potential Nasdaq uplisting. CEO Gene Cartwright highlighted significant progress in reducing liabilities and enhancing prospects for a Nasdaq listing and regulatory approvals in the US and China.

Guided Therapeutics, Inc. (OTCQB: GTHP) has successfully closed its Series F Preferred Stock Financing, raising $2.114 million in gross proceeds. The funds will primarily complete the FDA clinical trial for the LuViva® Advanced Cervical Scan, expected to begin in Q2 2021. The Series F shares, convertible at 25 cents, carry a 6% annual dividend, with potential additional dividends if certain conditions are unmet. CEO Gene Cartwright emphasized the importance of this funding for completing the FDA study and reducing company liabilities, setting the stage for a potential uplisting.

Guided Therapeutics, Inc. (OTCQB: GTHP) announced raising US $1.1 million in its Series F Preferred Stock Offering, targeting a minimum of $1 million. The funds will finalize a $750,000 payment to GPB Holdings and support an FDA clinical trial for the LuViva Advanced Cervical Scan. The completion of this study is crucial for the company. The Series F shares are convertible at 25 cents each and carry a 6% dividend, potentially increasing to 15% if certain conditions are unmet. CEO Gene Cartwright expressed confidence in the funding aiding company growth and advancing clinical trials.